A Study of Certolizumab Pegol to Evaluate Pharmacokinetics and Safety in Adult Healthy Chinese Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
This study will characterize the pharmacokinetics (PK) of certolizumab pegol (CZP) and evaluate safety of CZP in healthy Chinese subjects. 36 subjects will be randomized to receive one of 3 dose levels of CZP or placebo. The total study duration will be approximately 71-94 days for each subject.
Epistemonikos ID: d50f7d8ef9260dbdf609c8a7f5381b7da1c8c8e0
First added on: May 12, 2024